You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Biocatalytic production of precursors to lutein and zeaxanthin to address age related macular degeneration
SBC: EscaZyme Biochemicals, LLC Topic: NProject Summary Atrophic dry age related macular degeneration AMD is the leading cause of severe loss of vision for those over age Dietary supplements containing lutein and zeaxanthin are recommended by the NEI for those at risk of late AMD There has been a corresponding growth in demand for these two xanthophylls Lutein and zeaxanthin are currently sourced from marigolds grown mostl ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Bayesian Inference of Spacecraft Geometry and Pose
SBC: VISION SYSTEMS INC Topic: AF17AT007Space platforms are complex dynamical systems and there are many reasons to model them from ground telescope imagery as well as from space-based sensor platforms. One key motivation is to determine the operational state and configuration of the vehicle. Key questions such as did the solar panels fail to deploy, did the object begin to tumble unexpectedly may be addressed by a sufficiently detaile ...
STTR Phase I 2017 Department of DefenseAir Force -
SA FasL engineered human islets as a novel product for the treatment of type diabetes
SBC: FasCure Therapeutics LLC Topic: NIDDKPROJECT SUMMARY Type diabetes T D is a chronic autoimmune disorder that affects of population worldwide Exogenous insulin treatment is the standard of care for T D but often negatively affects the quality of life and is ineffective in preventing recurrent hyperglycemia episodes and chronic complications Recent studies show that human islet allografts can restore long term normoglycemia ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
TheraBracelet: The first and only wearable to instantly improve stroke hand function
SBC: TheraBracelet, Inc. Topic: NICHDProject SummaryPost stroke hand impairment is highly prevalent and severely restricts functional ability and independenceIn facteveryseconds a new stroke occursand stroke is recognized as the leading cause of long term disabilityYetthere is no assistive device to help hand function at homeevery dayduring activities of daily livingExisting devices such as hand opening orthoses are expensivee gMyomo ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy
SBC: STRYKAGEN CORPORATION Topic: NIAMSDESCRIPTION provided by applicant Duchenne Muscular Dystrophy DMD is a fatal muscle disease affecting in every male births DMD results from mutations in the gene encoding the dystrophin a kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and a transmembrane protein complex called the dystrophin associated glycoprotein ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum
SBC: DXDISCOVERY INC Topic: NIAIDDESCRIPTION provided by applicant The number of Lyme disease cases in the US has been recently estimated by the CDC at cases year This is major public health concern Currently available diagnostics rely on detection of the antibody response serology to Borrelia burgdorferi the causative agent of Lyme disease However serological tests are not accurate during the early stages of Ly ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Design, Reconfigure, and Evaluate Autonomous Models in Training
SBC: TIER 1 PERFORMANCE SOLUTIONS LLC Topic: AF15AT14ABSTRACT: The proliferation of autonomous- and human-machine systems necessitates the creation of new tools for system design and evaluation. Key among these are simulation testbeds that support interactions between multiple warfighters and systems, and methods for creating and integrating intelligent agent models into simulation environments. We see a significant opportunity to advance the state ...
STTR Phase I 2015 Department of DefenseAir Force -
Reverberation Mitigation of Speech
SBC: MINERVA SYSTEMS & TECHNOLOGIES LLC Topic: AF15AT17ABSTRACT: Speech recognition technology is in wide use today and has been successfully integrated in a number of applications. Most of these applications require a microphone located near the talker. However, when a distant microphone is used where the speaker is at some distance from the microphone as in a hands-free communication, or in a meeting room, there is a major problem with the captured ...
STTR Phase I 2015 Department of DefenseAir Force -
Prediction and Measurement of the Carbon Build-Up in Film-Cooled Rocket Engines
SBC: SIERRA ENGINEERING, INC. Topic: AF15AT21ABSTRACT: Sierra Engineering Inc. (Sierra) believes that existing chemical kinetic models can be efficiently incorporated into commercial CFD codes to predict the mixing, pyrolysis, soot formation and carbon deposition within film cooled rocket engines. During this Phase I STTR effort we will demonstrate that this analysis capability is practical and that we can generate appropriate model validati ...
STTR Phase I 2015 Department of DefenseAir Force -
Improving the therapeutic efficacy of a lead vaccine against plague using a novel adjuvant system
SBC: FasCure Therapeutics LLC Topic: NIAIDDESCRIPTION provided by applicant FasCure Therapeutics focuses on the development of adjuvant systems to generate prophylactic and therapeutic immune responses The major objective of this Phase STTR proposal is to reformulate a lead plague subunit vaccine with a novel adjuvant system to improve its protective efficacy Yersinia pestis is the causative agent of bubonic and pneumonic plague ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health